• Home
  • NEW DAY MEDICINE
  • 10 (72) 2024
  • 17 -10 (72) 2024 - Gulyamovna Y.R., Irgasheva N.M. - PATHOGENETIC MECHANISMS AND MODERN APPROACHES TO THE TREATMENT OF PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER

17 -10 (72) 2024 - Gulyamovna Y.R., Irgasheva N.M. - PATHOGENETIC MECHANISMS AND MODERN APPROACHES TO THE TREATMENT OF PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER

PATHOGENETIC MECHANISMS AND MODERN APPROACHES TO THE TREATMENT OF PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER

Gulyamovna Y.R.- Tashkent Pediatric Medical Institute

Irgasheva N.M.- Tashkent Pediatric Medical Institute

Resume

Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) are common conditions that negatively impact the quality of life of women. The etiology of PMS and PMDD is multifactorial, involving hormonal metabolism disruptions, altered sensitivity of the GABAergic system, and genetic predisposition. Modern treatment approaches include the use of selective serotonin reuptake inhibitors, combined hormonal contraception, and new neurosteroid medications. Cognitive-behavioral therapy and lifestyle modifications also play an important role. Further research into the role of neuroinflammation and the development of targeted therapies remains crucial to improving the quality of life for women with PMS and PMDD.

Key words: Premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), hormone metabolism, GABAergic system, genetic factors, neuroinflammation, allopregnanolone.

First page

114

Last page

121

For citation:Gulyamovna Y.R., Irgasheva N.M. - PATHOGENETIC MECHANISMS AND MODERN APPROACHES TO THE TREATMENT OF PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER//New Day in Medicine 10(72)2024 114-121 https://newdayworldmedicine.com/en/new_day_medicine/10-72-2024

List of References

  1. AlAshqar A., Lulseged B., Mason-Otey A. et al. Oxidative Stress and Antioxidants in Uterine Fibroids: Pathophysiology and Clinical Implications //Antioxidants (Basel). 2023 Mar;26(12):4.
  2. Bäckström T., Ekberg K., Hirschberg A. L. et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder //Psychoneuroendocrinology. 2021 Nov;133:105-426.
  3. Barone J.C., Butler M.P., Ross A. et al. A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy //Front Neuroendocrinol. 2023 Oct;71:101098.
  4. Beddig T., Reinhard I., Kuehner C. et al. Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder (PMDD) //Psychoneuroendocrinology. 2019 Nov;109:104372.
  5. Bertone-Johnson E. R. Chronic Inflammation and Premenstrual Syndrome: A Missing Link Found? //J Womens Health (Larchmt). 2016 Sep;25(9):857-8.
  6. Bixo M., Ekberg K., Poromaa I. S. et al. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial //Psychoneuroendocrinology. 2017 Jun;80:46-55.
  7. Cao S., Jones M., Tooth L. et al. Does premenstrual syndrome before pregnancy increase the risk of postpartum depression? Findings from the Australian Longitudinal Study on Women's Health //J Affect Disord. 2021 Jan;15(279):143-148.
  8. Carlini S.V., Lanza di Scalea T., McNally S.T. et al. Management of Premenstrual Dysphoric Disorder: A Scoping Review //Int J Womens Health. 2022;14:1783-1801.
  9. Carver C.M., Chuang S.H., Reddy D.S. et al. Zinc Selectively Blocks Neurosteroid-Sensitive Extrasynaptic δGABAA Receptors in the Hippocampus //J Neurosci. 2016 Aug;3/36(31):8070-7.
  10. Chan J.H., Lo C., Hsu C.D. et al. Premenstrual dysphoric symptoms and lifetime suicide experiences in patients with mood disorder //Gen Hosp Psychiatry. 2021 Jul-Aug;71:82-87.
  11. Comasco E., Kopp Kallner H., Bixo M. et al. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial //Am J Psychiatry. 2021 Mar 1;178(3):256-265.
  12. de Carvalho A. B., Cardoso T. A., Mondin T. C. et al. Prevalence and factors associated with Premenstrual Dysphoric Disorder: A community sample of young adult women //Psychiatry Res. 2018 Oct; 268:42-45.
  13. Dubey N., Hoffman J. F., Schuebel K. et al. The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder //Mol Psychiatry. 2017; Aug: 22(8):1172-1184.
  14. Gollapudi M., Thomas A., Yogarajah A. et al. Understanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD) //Cureus. 2024 Jun;16(6):e62788.
  15. Granda D., Szmidt M. K., Kaluza J. et al. Is Premenstrual Syndrome Associated with Inflammation, Oxidative Stress and Antioxidant Status? A Systematic Review of Case-Control and Cross-Sectional Studies //Antioxidants (Basel). 2021; Apr 14; 10(4).
  16. Hamidovic A., Mumford S., Schisterman E. et al. Neuroactive steroid hormone trajectories across the menstrual cycle in premenstrual dysphoric disorder (PMDD): the PHASE study //Mol Psychiatry. 2024 Apr 25.
  17. Hantsoo L., Sajid H., Murphy L. et al. Patient Experiences of Health Care Providers in Premenstrual Dysphoric Disorder: Examining the Role of Provider Specialty //J Womens Health (Larchmt). 2022 Jan; 31(1):100-109.
  18. Kaltsouni E., Fisher P. M., Dubol M. et al. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator //Neuropsychopharmacology. 2021 Jul; 46(8):1460-1467.
  19. Kancheva Landolt N., Ivanov K. et al. Short report: cognitive behavioral therapy - a primary mode for premenstrual syndrome management: systematic literature review //Psychol Health Med. 2021 Dec; 26(10):1282-1293.
  20. Kazzi B., Shankar B., Elder-Odame P. et al. A Woman's Heart: Improving Uptake and Awareness of Cardiovascular Screening for Middle-Aged Populations //Int J Womens Health. 2023;15:1171-1183.

    file

    download